 This is a Phase 1, open-label, dose-escalation trial of avelumab antibody targeting programmed death ligand 1 anti PD-L1 in Japanese subjects with metastatic or locally advanced solid tumors, followed by a consecutive expansion part in Asian subjects with gastric cancer. 